X

Trial Profile

A Randomized, Masked, Controlled Study of Intravitreal ILUVIEN Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluocinolone acetonide (Primary) ; Aflibercept
Indications Diabetic macular oedema
Focus Therapeutic Use
Acronyms NEW DAY
Sponsors Alimera Sciences

Most Recent Events

26 Oct 2023 According to an Alimera Sciences media release, topline data is anticipated in the first quarter of 2025.
10 Aug 2023 According to an Alimera Sciences media release, study completed enrollment with 306 patients.
23 Jun 2023 Planned End Date changed from 30 Jun 2024 to 31 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com